Coherus BioSciences-2026 JP Morgan Presentation.pdf

1、2026 Coherus Oncology,Inc.44TH ANNUAL J.P.MORGAN Healthcare ConferenceDenny Lanfear,Chairman and CEOOVERCOMING IMMUNE RESISTANCE IN CANCER2026 Coherus Oncology,Inc.Forward Looking StatementsExcept for the historical information contained herein,the matters set forth in this presentation are forward-

2、looking statements within the meaning of the“safe harbor”provisions of the Private Securities Litigation Reform Act of 1995.Forward-looking statements contained in this presentation may be identified by the use of words such as“may,”“will,”“should,”“expect,”“could,”“intend,”“target,”“estimate,”“pred

3、ict,”or“potential”or the negative of these terms or other similar expressions.These statements include,but are not limited to statements about growth in sales or revenues;ability of any of our pipeline product candidates to be first-to-market,first-to-data or first in-class in the future;expectation

4、s about being able to secure funding or to secure non-dilutive funding in future periods;statements about multiplying value;future data readouts or catalysts based on the clinical trials of Coherus Oncology,Inc.(“Coherus Oncology”);market size,market value,addressable market or opportunity and the n

5、umber of patients or incidence for particular indications;ability for a product candidate to disrupt a market;standard of care expectations;projections for cash runway;future collaborations;the degree of unmet need for particular indications;and the assumptions underlying or relating to such stateme

6、nts.Such forward-looking statements involve substantial risks and uncertainties that could cause Coherus Oncologys actual results,performance or achievements to differ significantly from any future results,performance or achievements expressed or implied by the forward-looking statements.Such risks